Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Trial Profile

Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine And Low Dose TBI With Disease-Risk Based Immunosuppression

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2016

At a glance

  • Drugs Fludarabine (Primary) ; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Amyloidosis; Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2012 Planned end date changed from 1 Dec 2003 to 1 Feb 2005 as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Planned end date (1 Dec 2003) added as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Actual patient number (159) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top